What it's for (Indications)
- Brimonidine tartrate 0.
- 2% and timolol 0.
- 5% ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who require concomitant therapy because of insufficient response to a single ophthalmic medication.
- This combination medication offers a dual mechanism of action, making it a valuable option for patients needing significant IOP reduction.
- The primary goal of treatment is to prevent further optic nerve damage and preserve visual field, which are critical in managing these chronic conditions.
- The decision to initiate combination therapy should be based on a thorough assessment of the patient's individual clinical profile, including baseline IOP, target IOP, and tolerability to previous treatments, to ensure optimal therapeutic outcomes and minimize potential risks.
- It is typically considered when monotherapy with either a beta-blocker or an alpha-2 adrenergic agonist does not achieve the desired therapeutic effect.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for brimonidine tartrate 0.2% and timolol 0.5% ophthalmic solution is one drop in the affected eye(s) twice daily, approximately 12 hours apart. To ensure proper administration and minimize systemic absorption, patients should be instructed to apply gentle pressure to the lacrimal sac at the medial canthus (punctal occlusion) immediately after instillation for at least one minute. This technique helps to reduce the likelihood of systemic side effects. If more than one topical ophthalmic medication is being used, the drugs should be administered at least five to ten minutes apart to prevent washout and ensure optimal absorption of each medication. Patients should be advised to remove contact lenses prior to instillation and wait at least 15 minutes before reinserting them, as the preservative benzalkonium chloride can be absorbed by soft contact lenses and cause irritation. Adherence to the prescribed dosage regimen is crucial for maintaining consistent intraocular pressure control. |
Safety & Warnings
Common Side Effects
- The most commonly reported ocular adverse reactions associated with brimonidine tartrate and timolol ophthalmic solution include ocular hyperemia, burning and stinging upon instillation, blurred vision, foreign body sensation, ocular pruritus, allergic conjunctivitis, conjunctival folliculosis, and dry eye.
- Other frequently reported systemic adverse reactions include headache, drowsiness, fatigue/asthenia, oral dryness, and taste perversion.
- Less common but potentially serious adverse effects can arise due to systemic absorption of either component.
- From timolol, these may include bradycardia, hypotension, syncope, exacerbation of asthma or chronic obstructive pulmonary disease (COPD), and cardiac arrhythmia.
- Brimonidine can contribute to central nervous system depression, leading to somnolence, lethargy, and in rare cases, apnea, particularly concerning in young children.
- Patients should be counseled on these potential side effects and advised to contact their healthcare provider if they experience severe or persistent symptoms.
Serious Warnings
- Black Box Warning: This product does not carry a formal FDA Black Box Warning. However, serious warnings regarding potential systemic effects, particularly due to the timolol component, warrant significant attention. Timolol, a beta-adrenergic blocker, can be absorbed systemically and may cause cardiovascular and pulmonary adverse reactions similar to those observed with systemic beta-blockers. These include severe respiratory reactions, such as bronchospasm in patients with bronchial asthma or severe COPD, and cardiac reactions, including the precipitation or exacerbation of heart failure, severe bradycardia, and hypotension. Therefore, caution is essential in patients with pre-existing cardiac or respiratory diseases, and the drug is contraindicated in severe cases. Furthermore, brimonidine, particularly in young children (under 2 years of age), can cause significant central nervous system depression, including somnolence, lethargy, and potentially apnea; hence, its use is contraindicated in this age group. Patients should be advised to seek immediate medical attention if they experience severe respiratory distress, chest pain, syncope, or profound dizziness.
- Systemic absorption of both brimonidine and timolol can lead to significant systemic effects, necessitating caution in patients with certain pre-existing conditions.
- Due to the timolol component, patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock should be carefully monitored.
- Beta-blockers can mask symptoms of hypoglycemia in diabetic patients and signs of hyperthyroidism.
- Brimonidine may cause significant central nervous system (CNS) depression, including somnolence and fatigue, and should be used with caution in patients with cardiovascular disease, depression, cerebral or coronary insufficiency, Raynaud's phenomenon, or orthostatic hypotension.
- The potential for systemic effects warrants careful consideration of concomitant medications, particularly other beta-blockers (oral or ophthalmic), alpha-adrenergic agonists, CNS depressants, or medications affecting cardiac conduction or blood pressure.
- Patients should be advised about potential impairment of the ability to operate machinery or drive due to somnolence or blurred vision.
- Remove contact lenses before administration and wait 15 minutes before reinserting.
- Caution is advised in patients with severe renal or hepatic impairment.
How it Works (Mechanism of Action)
Brimonidine tartrate and timolol ophthalmic solution combines two active pharmaceutical ingredients with distinct yet complementary mechanisms for reducing intraocular pressure (IOP). Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that acts by both decreasing the production of aqueous humor and increasing uveoscleral outflow. Its selective agonism of alpha-2 receptors leads to a reduction in cyclic AMP levels in the ciliary body, thereby reducing aqueous secretion. Concurrently, it facilitates an alternative pathway for aqueous drainage. Timolol maleate is a non-selective beta-adrenergic receptor blocker that primarily reduces IOP by decreasing aqueous humor production in the ciliary body. It achieves this by blocking beta-1 and beta-2 adrenergic receptors, which are involved in the secretion process. Timolol does not significantly affect aqueous outflow or accommodation. The combination of these two agents provides an additive IOP-lowering effect, targeting different physiological pathways responsible for aqueous humor dynamics, thus offering a more robust and sustained reduction in IOP compared to either agent used alone. This synergistic action is crucial for patients requiring greater IOP control.
Commercial Brands (Alternatives)
No other brands found for this formula.